Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 11/20 | 0.69 |
| ▸ | MAPK12 | P53778 | 11/20 | 0.69 |
| ▸ | MAPK11 | Q15759 | 11/20 | 0.69 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6098679 | 0.90 | MAPK13 (0.66) | MAPK13MAPK12MAPK11MAPK14NPC1 | |
| SCHEMBL6817276 | 0.86 | MAPK14 (0.76) | MAPK13MAPK12MAPK11MAPK14POLB | |
| SCHEMBL6821214 | 0.85 | MAPK14 (0.77) | MAPK13MAPK12MAPK11MAPK14POLB | |
| SCHEMBL6651799 | 0.85 | MAPK14 (0.84) | MAPK13MAPK12MAPK11MAPK14POLB | |
| SCHEMBL6096393 | 0.85 | MAPK13 (0.59) | MAPK13MAPK12MAPK11MAPK14POLB | |
| SCHEMBL6095615 | 0.85 | MAPK14 (0.72) | MAPK13MAPK12MAPK11MAPK14POLB | |
| SCHEMBL6397672 | 0.85 | MAPK14 (0.76) | MAPK13MAPK12MAPK11MAPK14POLB | |
| SCHEMBL6095607 | 0.85 | MAPK14 (0.72) | MAPK13MAPK12MAPK11MAPK14POLB | |
| SCHEMBL6813144 | 0.84 | MAPK14 (0.66) | MAPK13MAPK12MAPK11MAPK14ALDH1A1 | |
| SCHEMBL27497514 | 0.84 | MAPK14 (0.76) | MAPK13MAPK12MAPK11MAPK14POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034015-B2 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2006-04-25 | — | — | US | claimed |
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2003-06-26 | — | — | US | claimed |
| US-7034015-B2 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2006-04-25 | — | — | US | disclosed |
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | IL1B, IL1A, TNF | MAPK13 2918/4885MAPK12 2155/4885MAPK11 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.